Approaches and strategies for the treatment of influenza virus infections

Antiviral Chemistry and Chemotherapy

Volumn 10, Issue 4, 1999, Pages 155-185

  Colacino, Joseph M ^a   Staschke, Kirk A ^a   Laver, W Graeme ^b  

^a ELI LILLY AND COMPANY   (United States)

^b Biology and Environment   (Australia)

Author keywords

Amantadine; GS 4104; Haemagglutinin; Influenza virus; Neuraminidase; Ribavirin; Zanamivir

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; INFLUENZA VACCINE; OSELTAMIVIR; RIBAVIRIN; VIRUS ANTIGEN; VIRUS HEMAGGLUTININ; VIRUS SIALIDASE; ZANAMIVIR;

BACTERIAL INFECTION; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A; INFLUENZA VIRUS B; PNEUMONIA; POINT MUTATION; PRIORITY JOURNAL; REVIEW; SUPERINFECTION; VIRUS GENE; X RAY CRYSTALLOGRAPHY;

EID: 0032813142     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632029901000402     Document Type: Review

References (222)

1. Abe T, Hatta T, Yamakawa H, Takai K, Yokota T & Takaku H (1997) Synthesis and anti-influenza virus-A activity of circular dumbbell RNA DNA chimeric oligonucleotides. Nucleic Acids Symposium Series 37:219-220.
2. Abe T, Suzuki S, Hatta T, Yokota T & Takaku H (1998a) Specific inhibition of influenza virus RNA polymerase and nucleoprotein gene expression by liposomally encapsulated antisense phosphorothioate oligonucleotides in MDCK cells. Antiviral Chemistry & Chemotherapy 9:253-262.
3. Abe T, Hatta T, Takai K, Nakashima H, Yokota T & Takaku H (1998b) Inhibition of influenza virus replication by phosphorothioate and liposomally endocapsulated oligonucleotides. Nucleosides Nucleotides 17:471-478.
4. Alonso-Caplen FV & Krug RM (1991) Regulation of the extent of splicing of influenza virus NS1 mRNA: Role of the rates of splicing and of the nucleocytoplasmic transport of NS1 mRNA. Molecular and Cellular Biology 11:1092-1098.
5. Bantia S, Ghate AA, Ananth SL, Babu YS, Air GM & Walsh GM (1998) Generation and characterization of a mutant of influenza A virus selected with the NA inhibitor BCX-140. Antimicrobial Agents and Chemotherapy 42:801-807.
6. Belshe RB, Burk B, Newman F, Ceruti RL & Sim IS (1989) Resistance of influenza A virus to amantadine and rimantadine: Results of one decade of surveillance. Journal of Infectious Diseases 159:430-435.
7. Bender C, Hall H, Huang J, Klimov A, Cox N, Hay A, Gregory V, Cameron K, Lim W & Sabbarao K (1999) Characterization of the surface proteins of influenza A (H5N1) viruses isolated from humans in 1997-1998. Virology 254:1154-1123.
8. Bethell RC, Gray NM & Penn CR (1995) The kinetics of the acid-induced conformational change of influenza virus haemagglutinin can be followed using 1,1′-bis(4-anilino-5-naphthalenesulphonic acid). Biochemical and Biophysical Research Communications 206:355-361.
9. Birch GM, Colacino JM, Ehlhardt WJ & Balzarini J (1995) The intracellular formation of a mononucleotide of the anti-influenza agent 1,3,4-thiadiazol-2-ylcyanamide (LY217896). Antiviral Chemistry & Chemotherapy 6:127-137.
10. Blake DR, Hall ND, Bacon PA, Dieppe PA, Halliwell B & Gutteridge JM (1983) Effect of a specific iron chelating agent on animal models of inflammation. Annals of the Rheumatic Diseases 42:89-93.
11. Blick TJ, Tiong T, Sahasrabudhe A, Varghese JN, Colman PM, Hart GJ, Bethell RC & McKimm-Breschkin JL (1995) Generation and characterization of an influenza virus NA variant with decreased sensitivity to the NA-specific inhibitor 4-guanidino-Neu5Ac2en. Virology 214:475-484.
12. Bodian DL, Yamasaki RB, Buswell RL, Stearns JF, White JM & Kuntz ID (1993) Inhibition of the fusion-inducing conformational change of influenza HA by benzoquinones and hydroquinones. Biochemistry 32:2967-2978.
13. Braam J, Ulmanen I & Krug RM (1983) Molecular model of a eukaryotic transcription complex: Functions and movements of influenza P proteins during capped RNA-primed transcription. Cell 34:609-618.
14. Bullough PA, Hughson FM, Skehel JJ & Wiley DC (1994) Structure of influenza virus haemagglutinin at the pH of membrane fusion. Nature 371:37-43.
15. Burnet FM & Stone JD (1947) The receptor destroying enzyme of V. Cholerae. Journal of Experimental Biology and Medicine 25:227-233.
16. Calfee DP & Hayden FG (1998) New approaches to influenza chemotherapy. NA Inhibitors. Drugs 56:537-553.
17. Carr CM & Kim PS (1993) A spring-loaded mechanism for the conformational change of influenza HA. Cell 73:823-832.
18. Chand P, Babu YS, Bantia S, Chu N, Cole LB, Kotian PL, Laver WG, Montgomery JA, Pathak VP, Petty SL, Shrout DP, Walsh DA & Walsh GM (1997) Design and synthesis of benzoic acid derivatives as influenza NA inhibitors using structure-based drug design. Journal of Medicinal Chemistry 40:4030-4052.
19. Chen J, Lee KH, Steinhauer DA, Stevens DJ, Skehel JJ & Wiley DC (1998) Structure of the HA precursor cleavage site, a determinant of influenza pathogenicity and the origin of the labile conformation. Cell 95:409-417.
20. Chung TDY, Cianci C, Hagen M, Terry B, Matthews JT, Krystal M & Colonno RJ (1994) Biochemical studies on capped RNA primers identify a class of oligonucleotide inhibitors of the influenza virus RNA polymerase. Proceedings of the National Academy of Sciences, USA 91:2372-2376.
21. Ciampor F, Thompson CA, Grambas S & Hay AJ (1992) Regulation of pH by the M2 protein of influenza A viruses. Virus Research 22:247-258.
22. Codington JF, Doerr IL & Fox JJ (1964) Nucleosides. XVIII. Synthesis of 2′-fluorothymidine, 2′-fluorodeoxyuridine, and other 2′-halogen-2′-deoxy nucleosides. Journal of Organic Chemistry 29:558-564.
23. Cohen AT, Togo Y, Khakoo R, Waldman R & Sigel M (1976) Comparative clinical and laboratory evaluation of the prophylactic capacity of ribavirin, amantadine hydrochloride, and placebo in induced human influenza type A. Journal of Infectious Diseases 133: Suppl. A114-120.
24. Colacino JM (1996) Resistance of influenza A and B viruses to 4-guanidino-Neu5Ac2en. In Options for the Control of Influenza III, pp. 741-747.Edited by LE Brown, AW Hampson & RG Webster. Amsterdam: Elsevier Science.
25. Colacino JM, DeLong DC, Nelson JR, Spitzer WA, Tang J, Victor F & Wu CYE (1990) Evaluation of the anti-influenza virus activities of 1,3,4-thiadiazol-2-ylcyanamide (LY217896) and its sodium salt. Antimicrobial Agents and Chemotherapy 34:2156-2163.
26. Colacino JM, Birch GM & Tang JC (1993) Cellular metabolism and anti-influenza activity of 1,3,4-thiadiazol-2-ylcyanamide (LY217896). Antiviral Chemistry & Chemotherapy 4:271-280.
27. Colacino JM, Chirgadze NY, Garman E, Murti KG, Loncharich RJ, Baxter AJ, Staschke KA & Laver WG (1997) A single sequence change destabilizes the influenza virus NA tetramer. Virology 236:66-75.
28. Colman PM (1994) Influenza virus NA: structure, antibodies, and inhibitors. Protein Science 3:1687-1696.
29. Colman PM, Varghese JN & Laver WG (1983) Structure of the catalytic and antigenic sites in influenza virus NA. Nature 303:41-44.
30. Compans RW, Dimmock NJ & Meier-Ewert H (1969) Effect of antibody to NA on the maturation and hemagglutinating activities of an influenza A2 virus. Journal of Virology 4:528-534.
31. Courtney RJ, Steiner SM & Benyesh-Melnick M (1973) Effects of 2-deoxy-D-glucose on herpes simplex virus replication. Virology 42:447-455.
32. Cox NJ & Fukuda K (1998). Influenza. Emerging Infectious Diseases 12:27-38.
33. Daniels RS, Downie JC, Hay AJ, Knossow M, Skehel JJ, Wang ML & Wiley DC (1985) Fusion mutants of the influenza virus HA glycoprotein. Cell 40:431-439.
34. Detjen BM, St Angelo C, Katze MG & Krug RM (1987) The three influenza virus polymerase (P) proteins not associated with viral nucleocapsids in the infected cell are in the form of a complex. Journal of Virology 61:16-22.
35. Ehlhardt WJ, Wheeler WJ, Breau AP, Chay SH & Birch GM (1993) Biotransformation of the antiviral agent 1,3,4-thiadiazol-2-ylcyanamide (LY217896) and characteristics of a mesoionic ribose metabolite. Drug Metabolism and Disposition 21:162-170.
36. Eisenberg EJ, Bidgood A & Cundy KC (1997) Penetration of GS 4071, a novel influenza NA inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug GS 4104. Antimicrobial Agents and Chemotherapy 41:1949-1952.
37. Enami M, Sharma G, Benham C & Palese P (1991) An influenza virus containing nine different RNA segments. Virology 185:291-298.
38. Engelhardt JA, Brodhecker CA, Colacino JM, Tang J & Spitzer WA (1991) Morphopathogenesis of influenza A pneumonia in mice treated with LY217896 or amantadine. Antiviral Research 1 (Suppl.):141.
39. Erikkson B, Helgstrand E, Johansson NG, Larsson A, Misiorny A, Noren JO, Philipson L, Stenberg K, Stening G, Stridh S & Oberg B (1977) Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate. Antimicrobial Agents and Chemotherapy 11:946-951.
40. Flashner M, Kessler J & Tannebaum SW (1983) The interaction of substrate-related ketals with bacterial and viral NAs. Archives of Biochemistry and Biophysics 221:188-196.
41. Gamian A, Chomik M, Laferriere CA & Roy R (1991) Inhibition of influenza A virus HA and induction of interferon by synthetic sialylated glycoconjugates. Canadian Journal of Microbiology 37:233-237.
42. Garcia-Sastre A, Egorov A, Matassov D, Brandt S, Levy DE, Durbin JE, Palese P & Muster T (1998) Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology 252:324-330.
43. Garten W, Bosch FX, Linder D, Rott R & Klenk HD (1981) Proteolytic activation of the influenza virus HA: the structure of the cleavage site and the enzymes involved in cleavage. Virology 115:361-374.
44. Ghandi SS, Stanley P, Taylor SM & White DO (1972) Inhibition of influenza virus glycoprotein synthesis by sugars. Microbios 5:41-50.
45. Glanzer BI, Gyorgydeak Z, Bernet B & Vasella A (1991) Analogues of sialic acids as potential sialidase inhibitors. Synthesis of C6 and C7 analogues of N-acetyl-6-amino-2,6-dideoxyneuraminic acid. Helvetica Chimica Acta 74:343-369.
46. Glushkov RG (1992) Arbidol. Drugs of the Future 17:1079-1081.
47. Gubareva LV, Bethell R, Hart GJ, Murti KG, Penn CR & Webster RG (1996) Characterization of mutants of influenza A virus selected with the NA inhibitor 4-guanidino-Neu5Ac2en. Journal of Virology 70:1818-1827.
48. Gubareva LV, Robinson MJ, Bethell RC & Webster RG (1997) Catalytic and framework mutations in the NA active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. Journal of Virology 71:3385-3390.
49. Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC & Webster RG (1998) Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. Journal of Infectious Diseases 178:1257-1262.
50. Guinea R & Carrasco L (1995) Requirement for vacuolar proton-ATPase activity during entry of influenza virus into cells. Journal of Virology 69:2306-2312.
51. Guschlbauer W & Jankowski K (1980) Nucleoside conformation is determined by the electronegativity of the sugar substituent. Nucleic Acids Research 8:1421-1433.
52. Haskell TH, Peterson FE, Watson D, Plessas NR & Culbertson T (1970) NA inhibition and viral chemotherapy. Journal of Medicinal Chemistry 13:697-704.
53. Hatada E, Saito S & Fukuda R (1999) Mutant influenza viruses with a defective NS1 protein cannot block the activation of PKR in infected cell. Journal of Virology 73:2425-2433.
54. Hay AJ (1992) The action of adamantanamines against influenza A viruses: Inhibition of the M2 ion channel protein. Seminars in Virology 3:21-30.
55. Hay AJ, Wolstenholme AJ, Skehel JJ & Smith MH (1985) The molecular basis of the specific anti-influenza action of amantadine. EMBO Journal 4:3021-3024.
56. Hayden FG, Belshe RB, Clover RD, Hay AJ, Oakes MG & Soo W (1989) Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. New England Journal of Medicine 321:1696-1702.
57. Hayden FG, Rollins BS & Hay AJ (1990) Anti-influenza virus activity of the compound LY253963. Antiviral Research 14:25-38.
58. Hayden FG, Tunkel AR, Treanor JJ, Betts RF, Allerheiligen S & Harris J (1994) Oral LY217896 for prevention and experimental influenza A virus infection an illness in humans. Antimicrobial Agents and Chemotherapy 38:1178-1181.
59. Hayden FG, Treanor JJ, Betts RF, Lobo M, Esinhart JD & Hussey EK (1996) Safety and efficacy of the NA inhibitor GG167 in experimental human influenza. Journal of the American Medical Association 275:295-299.
60. Hayden FG, Osterhaus ADME, Treanor JJ, Fleming DM, Aoki FY, Nicholson KG, Bohnen AM, Hirst HM, Keene O & Wightman K (1997) Efficacy and safety of the NA inhibitor zanamivir in the treatment of influenza virus infections. GG167 Influenza Study Group. New England Journal of Medicine 337:874-880.
61. Hernandez LD, Hoffman LR, Wolfsberg TG & White JM (1996) Virus-cell and cell-cell fusion. Annual Review of Cell and Developmental Biology 12:627-661.
62. Herz C, Stavnezer E, Krug RM & Gurney T (1981) Influenza virus, an RNA virus, synthesizes its messenger RNA in the nucleus of infected cells. Cell 26:391-400.
63. Hill CL, Hartnup M, Faraj M, Weeks M, Prosser-McCartha CM, Brown RB Jr, Kadkhodayan M, Sommadossi JP & Schmazi RF (1990a) Polyoxometalates as inorganic anti-HIV-1 compounds. Structure-activity relationships. In: Advances in Chemotherapy of AIDS, pp. 33-41. Edited by RB Diasio & JP Sommadossi. New York: Pergamon Press.
64. Hill CL, Weeks MS & Schinazi RF (1990b) Anti-HIV activity, toxicity, and stability studies of representative structural families of polyoxometalates. Journal of Medicinal Chemistry 33:2767-2772.
65. Hirst GK (1942) Adsorption of influenza HAs and virus by red blood cells. Journal of Experimental Medicine 76:195-209.
66. Ho PPK & Walters CP (1970) Inhibitors of influenza virus induced RNA polymerase. Annals of the New York Academy of Sciences 173:438-443.
67. Hoffman LR, Kuntz ID & White JM (1997) Structure-based identification of an inducer of the low-pH conformational change in the influenza virus HA: irreversible inhibition of infectivity. Journal of Virology 71:8808-8820.
68. Hosoya M, Balzarini J, Shigeta S & De Clercq E (1991) Differential inhibitory effects of sulfated polysaccharides and polymers on the replication of various myxoviruses and retroviruses, depending on the comparison of the target amino acid sequences of the viral envelope glycoproteins. Antimicrobial Agents and Chemotherapy 35:2515-2520.
69. Hosoya M, Shigeta S, Ishii T, Suzuki H & De Clercq E (1993) Comparative inhibitory effects of various nucleoside and nonnucleoside analogues on replication of influenza virus types A and B in vitro and in ovo. Journal of Infectious Diseases 168:641-646.
70. Hruskova J, Jary T, Danes L, Jelinkova A & Novak M (1975) Effect of 6-amino-6-deoxy-D-glucose hydrochloride on influenza infection in mice. Acta Virologica 19:47-51.
71. Huang RTC, Rott R & Klenk HD (1981) Influenza viruses cause hemolysis and fusion of cells. Virology 110:243-247.
72. Huang TS, Palese P & Krystal M (1990) Determination of influenza virus proteins required for genome replication. Journal of Virology 64:5669-5673.
73. Huffman JH, Sidwell RW, Khare GP, Witkowski JT, Allen LB & Robins RK (1973) In vitro effect of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole, ICN 1229) on deoxyribonucleic and ribonucleic viruses. Antimicrobial Agents and Chemotherapy 3:235-241.
74. Huffman JH, Sidwell RW, Barnard DL, Morrison A, Otto MJ, Hill CL & Schinazi RF (1997) Influenza virus-inhibitory effects of a series of germanium- and silicon-centered polyoxometalates. Antiviral Chemistry & Chemotherapy 8:75-83.
75. Ichimura H & Levy JA (1995) Polymerase substrate depletion: a novel strategy for inhibiting the replication of the human immunodeficiency virus. Virology 211:554-560.
76. Ikeda S, Neyts J, Yamamoto N, Burrer B, Theobald B, Bossard G, Henson G, Abrams M, Picker D & De Clercq E (1993) In vitro activity of a novel series of polyoxosilicotungstates against human myxo-, herpes-, and retroviruses. Antiviral Chemistry & Chemotherapy 4:253-262.
77. Jakeman KJ, Tisdale M, Russell S, Leone A & Sweet C (1994) Efficacy of 2′-deoxy-2′-fluororibosides against influenza A and B viruses in ferrets. Antimicrobial Agents and Chemotherapy 38:1864-1867.
78. Jedrzejas MJ, Singh S, Brouillette WJ, Laver WG, Air GM & Luo M (1995) Structures of aromatic inhibitors of influenza virus NA. Biochemistry 34:3144-3150.
79. Judd AK, Sanchez A, Kharitonenkov I, Mosconna A, Nasser E & Bucher DJ (1992) M-protein peptides of influenza virus: application as antiviral agents. In: Peptides, pp. 694-696. Edited by JA Smith & JE Rivier. Leiden: ESCOM.
80. Judd AK, Sanchez A, Bucher DJ, Huffman JH, Bailey K & Sidwell RW (1997) In vivo anti-influenza virus activity of a zinc finger peptide. Antimicrobial Agents and Chemotherapy 41:687-692.
81. Kaluza G, Scholtissek C & Rott R (1972) Inhibition of the multiplication of enveloped RNA-viruses by glucosamine and 2-deoxy-D-glucose. Journal of General Virology 14:251-259.
82. Kati WM, Saldivar S, Mohamadi F, Sham HL, Laver WG & Kohlbrenner WE (1998) GS 4071 is a slow-binding inhibitor of influenza NA from both A and B strains. Biochemical and Biophysical Research Communications 17:244:408-413.
83. Kelm S, Paulson JC, Rose U, Brossmer R, Schmid W, Bandgar BP, Schreiner E, Hartmann M &, Zbiral E (1992) Use of sialic acid analogues to define functional groups involved in binding to the influenza virus HA. European Journal of Biochemistry 205:147-153.
84. Kido H, Yokogoshi Y, Sakai K, Tashiro M, Kishino Y, Fukutomi A & Katunuma N (1992) Isolation and characterization of a novel trypsin-like protease found in rat bronchiolar epithelial Clara cells: A possible activator of the viral fusion glycoprotein. Journal of Biological Chemistry 267:13573-13579.
85. Kido H, Sakai K, Kishino Y & Tashiro M (1993) Pulmonary surfactant is a potential endogenous inhibitor of proteolytic activation of Sendai virus and influenza A virus. FEBS Letters 322:115-119.
86. Kilbourne ED (1959) Inhibition of influenza virus multiplication with a glucose antimetabolite (2-deoxy-D-glucose). Nature 183:271-272.
87. Kilbourne ED, Palese P & Schulman JL (1975) Inhibition of viral NA as a new approach to the prevention of influenza. Perspectives in Virology 9:99-113.
88. Kim GS, Judd DA, Hill CL & Schinazi RF (1994) Synthesis, characterization and biological activity of a new potent class of anti-HIV agents, the peroxonionbium substituted heteropolytungstates. Journal of Medicinal Chemistry 37:816-820.
89. Kim CU, Lew W, Williams MA, Liu HT, Zhang LJ, Swaminathan S, Bischofberger N, Chen MS, Mendel DB, Tai, CY, Laver WG & Stevens RC (1997) Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. Journal of the American Chemical Society 119:681-690.
90. Kim CU, Lew W, Williams MA, Wu H, Zhang L, Chen X, Escarpe PA, Mendel DB, Laver WG & Stevens RC (1998) Structure-activity relationship studies of novel carbocyclic influenza NA inhibitors. Journal of Medicinal Chemistry 41:2451-2460.
91. Klenk HD & Rott R (1988) The molecular biology of influenza virus pathogenicity. Advances in Virus Research 34:247-281.
92. Klenk HD, Scholtissek C & Rott R (1972) Inhibition of glycoprotein biosynthesis of influenza virus by D-glucosamine and 2-deoxy-D-glucose. Virology 49:723-734.
93. Klenk HD, Wollert W, Rott R & Scholtissek C (1974) Association of influenza virus proteins with cytoplasmic fractions. Virology 57:28-41.
94. Klenk HD, Rott R, Orlich M & Blodorn J (1975) Activation of influenza A viruses by trypsin treatment. Virology 68:426-439.
95. Krakoff IH (1965) Increase in uric acid biosynthesis produced by 2-substituted thiadiazoles. Arthritis Rheumatism 8:836-839.
96. Krug RM, Ueda M & Palese P (1975) Temperature-sensitive mutants of influenza WSN virus defective in virus-specific RNA synthesis. Journal of Virology 16:790-796.
97. Krug RM (Editor) (1989) The Influenza Viruses. New York: Plenum Press.
98. Kurtz S, Luo G, Hahnenberger KM, Brooks C, Gecha O, Ingalls K, Numata K & Krystal M (1995) Growth impairment resulting from expression of influenza virus M2 protein in Saccharomyces cerevisiae: Identification of a novel inhibitor of influenza viruses. Antimicrobial Agents and Chemotherapy 39:2204-2209.
99. Laver WG & Valentine RC (1969) Morphology of the isolated HA and NA subunits of influenza virus. Virology 38:105-119.
100. Laver WG (1978) Crystallization and peptide maps of NA "heads" from H2N2 and H3N2 influenza virus. Virology 51:383-391.
101. Lazarowitz SG & Choppin PW (1975) Enhancement of the infectivity of influenza A and B viruses by proteolytic cleavage of the hemagglutinin polypeptide. Virology 68:440-454.
102. Levine AJ (1992) The influenza A virus. In: Viruses, pp. 155-175. New York: Scientific American Library.
103. Li W, Escarpe PA, Eisenberg EJ, Cundy KC, Sweet C, Jakeman KJ, Merson J, Lew W, Williams M, Zhang L, Kim CU, Bischofberger N, Chen MS & Mendel DB (1998) Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus NA inhibitor GS 4071. Antimicrobial Agents and Chemotherapy 42:647-653.
104. Liu C, Eichelberger MC, Compans RW & Air GM (1995) Influenza type A virus NA does not play a role in viral entry, replication, assembly, or budding. Journal of Virology 69:1099-1106.
105. Lu Y, Wambach M, Katze MG & Krug RM (1995) Binding of the influenza virus NS1 protein to double-stranded RNA inhibits the activation of the protein kinase that phosphorylates the elF-2 translation initiation factor. Virology 214:222-228.
106. Luo M, MJ Jedrzejas, S Singh, CL White, WJ Brouillette, GM Air & WG Laver. (1995). Benzoic acid inhibitors of influenza virus NA. Acta Crystallographica D51:504-510.
107. Luo G, Colonno R & Krystal M (1996) Characterization of a HA-specific inhibitor of influenza A virus. Virology 226:66-76.
108. Luo G, Torri A, Harte WE, Danetz S, Cianci C, Tiley L, Day S, Mullaney D, Yu KL, Ouellet C, Dextraze P, Meanwell N, Colonno R & Krystal M (1997) Molecular mechanism underlying the action of a novel fusion inhibitor of influenza A virus. Journal of Virology 71:4062-4070.
109. McCauley JW, Pullen LA, Forsyth M, Penn CR & Thomas GP (1995) 4-Guanidino-Neu5Ac2en fails to protect chickens from infection with highly pathogenic avian influenza virus. Antiviral Research 27:179-186.
110. McKimm-Breschkin JL, Blick TJ, Sahasrabudhe A, Tiong T, Marshall D, Hart GJ, Bethell RC & Penn CR (1996) Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en. Antimicrobial Agents and Chemotherapy 40:40-46.
111. McKimm-Breschkin JL, Sahasrabudhe A, Blick TJ, McDonald M, Colman PM, Hart GJ, Bethell RC & Varghese JN (1998) Mutations in a conserved residue in the influenza virus NA active site decreases sensitivity to Neu5Ac2en-derived inhibitors. Journal of Virology 72:2456-2462.
112. Madren LK, Shipman C Jr & Hayden FG (1995) In vitro inhibitory effects of combinations of anti-influenza agents. Antiviral Chemistry & Chemotherapy 6:109-113.
113. Maeda T & Ohnishi SI (1980) Activation of influenza viruses by acidic media causes hemolysis and fusion of erythrocytes. FEBS Letters 122:283-287.
114. Magnussen RC, Douglas RG Jr, Betts RF, Roth RK & Meagher MP (1977) Double-blind evaluation of oral ribavirin (Virazole) experimental influenza A virus infections in volunteers. Antimicrobial Agents and Chemotherapy 12:498-502.
115. Malinoski F & Stollar V (1981) Inhibitors of IMP dehydrogenase prevent Sindbis virus replication and reduce GTP levels in Aedes albopictus cells. Virology 110:281-291.
116. Martin K & Helenius A (1991) Nuclear transport of influenza virus ribonucleoproteins: The viral matrix protein (M1) promotes export and inhibits import. Cell 67:117-130.
117. Meindl P & Tuppy H (1969) 2-Deoxy-2,3-dehdrosialic acids. II. Competitive inhibition of V. cholerae NA by 2-deoxy-2,3-dehydro-N-acylneuraminic acids. Hoppe-Seylers Zeitschrift für Physiologische Chemie 350:1088-1092.
118. Meindl P, Bodo G, Lindner J & Palese P (1971) Influence of 2-deoxy-2,3-dehydro-N-acetylneuraminic acid on myxovirus neuraminidases and the replication of influenza and Newcastle disease virus. Zeitschrift für Naturforsch 26:792-797.
119. Meindl P, Bodo G, Palese P, Schulman J & Tuppy H (1974) Inhibition of NA activity by derivatives of 2-deoxy-2,3-dehydro-N-acetylneuraminic acid. Virology 58:457-463.
120. Mendel DB, Tai CY, Escarpe PA, Li W, Sidwell RW, Huffman JH, Sweet C, Jakeman KJ, Merson J, Lacy SA, Lew W, Williams MA, Zhang L, Chen MS, Bischofberger N & Kim CU (1998) Oral administration of a prodrug of the influenza virus NA inhibitor GS 4071 protects mice and ferrets against influenza virus infection. Antimicrobial Agents and Chemotherapy 42:640-646.
121. Montgomery JA, Shortnacy A, Carson DA & Secrist JA (1986) 9-(2-deoxy-2-fluoro-(-D-arabinofuranosyl)guanine: A metabolically stable cytotoxic analogue of 2′-deoxyguanosine. Journal of Medicinal Chemistry 29:2389-2392.
122. Murakami M, Ikeda K & Achiwa K (1996) Chemoenzymatic synthesis of neuraminic acid analogs structurally varied at C-5 and C-9 as potential inhibitors of the sialidase from influenza virus. Carbohydrate Research 280:101-110.
123. Nagai T, Miyaichi Y, Tomimori T, Suzuki Y & Yamada H (1992) In vivo anti-influenza virus activity of plant flavonoids possessing inhibitory activity for influenza virus sialidase. Antiviral Research 19:207-217.
124. Nagai T, Moriguchi R, Suzuki Y, Tomimori T & Yamada H (1995) Mode of action of the anti-influenza virus activity of plant flavonoid, 5,7,4′-trihydroxy-8-methoxyflavone, from the roots of Scutellaria baicalensis. Antiviral Research 26:11-25.
125. Nasser EH, Judd AK, Sanchez A, Anastasiou D & Bucher DJ (1996) Antiviral activity of influenza virus M1 zinc finger peptides. Journal of Virology 70:8639-8644.
126. Nelson JA, Rose LM & Bennet LL (1977) Mechanism of action of 2-amino-1,3,4-thiadiazole (NSC 4728). Cancer Research 27:182-187.
127. Ni L, Boudinot FD, Boudinot SG, Henson GW, Bossard GE, Martellucci SA, Ash PW, Fricker SP, Darkes MC, Theobald BR, Hill CL & Schinazi RF (1994) Pharmacokinetics of antiviral polyoxometalates in rats. Antimicrobial Agents and Chemotherapy 38:504-510.
128. Nichol ST, Penn CR & Mahy BWJ (1981) Evidence for the involvement of influenza A (Four Plaque Rostock) virus protein P2 in ApG and mRNA-primed in vitro RNA synthesis. Journal of General Virology 57:407-413.
129. Nohle U, Beau JM & Schauer R (1982) Uptake, metabolism and excretion of orally and intravenously administered, double-labeled N-glycoloylneuraminic acid and single-labeled 2-deoxy-2,3-dehydro-N-acetylneuraminic acid in mouse and rat. European Journal of Biochemistry 126:543-548.
130. Ochiai H, Sakai S, Hirabayashi T, Shimizu Y & Terasawa K (1995) Inhibitory effect of bafilomycin A1, a specific inhibitor of vacuolar-type proton pump, on the growth of influenza A and B viruses in MDCK cells. Antiviral Research 27:425-430.
131. Oda T, Akaike T, Hamamoto T, Suzuki F, Hirano T & Maeda H (1989) Oxygen radicals in influenza-induced pathogenesis and treatment with pyran polymer-conjugated SOD. Science 244:974-976.
132. O'Neill RE, Talon J & Palese P (1998) The influenza virus NEP (NS2 protein) mediates the nuclear export of viral ribonucleoproteins. EMBO Journal 17:288-296.
133. Orozco-Topete T, Sierra-Madero J, Cano-Dominguez C, Kershenovich J, Ortiz-Pedroza G, Vazquez-Valls E, Garcia-Cosio C, Soria-Cordoba A, Armendariz AM, Teran-Toledo X, Romo-Garcia J, Fernandez H & Rozhon EJ (1997) Safety and efficacy of Virend (Rm) for topical treatment of genital and anal herpes simplex lesions in patients with AIDS. Antiviral Research 35:91-103.
134. Ott S & Wunderli-Allenspach H (1994) Effect of the virostatic norakin (triperiden) on influenza virus activities. Antiviral Research 24:37-42.
135. Oxford JS (1975) Inhibition of the replication of influenza A and B viruses by a nucleoside analogue (ribavirin). Journal of General Virology 28:409-414.
136. Oxford JS & Perrin DD (1974) Inhibition of particle-associated RNA-dependent RNA polymerase activity of influenza viruses by chelating agents. Journal of General Virology 23:59-71.
137. Oxford JS & Perrin DD (1977). Influenza RNA transcriptase inhibitors. Studies in vitro and in vivo. Annals of the New York Academy of Sciences 284:613-623.
138. Palese P & Compans RW (1976) Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): mechanism of action. Journal of General Virology 33:159-163.
139. Palese P & Schulman JL (1977) Inhibitors of viral NA as potential antiviral drugs. In: Chemoprophylaxis and virus infections of the respiratory tract, Vol. I, pp. 189-205. Edited by JS Oxford. Cleveland: CRC Press.
140. Palese P, Tobita K, Ueda M & Compans RW (1974a) Characterization of temperature-sensitive influenza virus mutants defective in NA. Virology 61:397-410.
141. Palese P, Schulman JL, Bodo G & Meindl P (1974b) Inhibition of influenza and parainfluenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA). Virology 59:490-498.
142. Penn CR, Barnet J, Bethell RC, Fenton R, Gearing KL, Healy N & Jowett AJ (1996) Selection of influenza virus with reduced in vitro to the NA inhibitor GG167 (4-guanidino-Neu5Ac2en): changes in haemagglutinin may compensate for loss of NA activity. In: Options for the Control of Influenza III, pp. 735-740. Edited by LE Brown, AW Hampson & RG Webster. Amsterdam: Elsevier Science.
143. Pinto LH, Holsinger LJ & Lamb RA (1992) Influenza virus M2 protein has ion channel activity. Cell 69:517-528.
144. Plotch SJ, O'Hara B, Morin J, Palant O, LaRocque J, Bloom JD, Lang SA Jr, DiGrandi MJ, Bradley M, Nilakantan R & Gluzman Y (1998) Inhibition of influenza A virus replication by compounds interfering with the fusogenic function of the viral HA. Journal of Virology 73:140-151.
145. Presber HW, Schroeder C, Hegenscheid B, Heider H, Reefschlager J & Rosenthal HA (1984) Antiviral activity of norakin (triperiden) and related anticholinergic antiparkinsonism drugs. Acta Virologica 28:501-507.
146. Prosch S, Heider H, Schroeder C & Kruger DH (1988) Mutations in the HA gene associated with influenza virus resistance to norakin. Archives of Virology 102:125-129.
147. Prosch S, Heider H, Schroeder C, Shilov AA, Sinitzyn BV, Blinov VM, Kruger DH & Frommel C (1990) Mapping mutations in influenza A virus resistant to norakin. FEBS Letters 267:19-21.
148. Reid AH, Fanning TG, Hultin JV & Taubenberger JK (1999) Origin and evolution of the 1918 "Spanish" influenza virus HA gene. Proceedings of the National Academy of Sciences, USA 96:1651-1656.
149. Rollins BS, Elkhatieb AHA & Hayden FG (1993) Comparative anti-influenza virus activity of 2′-deoxy-2′-fluororibosides in vitro. Antiviral Research 21:357-368.
150. Rott T, Becht H & Orlich M (1974) The significance of influenza virus NA in immunity. Journal of General Virology 22:35-41.
151. Ryan DM, Ticehurst J, Dempsey MH & Penn CR (1994) Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral NA (sialidase). Antimicrobial Agents and Chemotherapy 38:2270-2275.
152. Ryan DM, Ticehurst J & Dempsey MH (1995) GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is a potent inhibitor of influenza virus in ferrets. Antimicrobial Agents and Chemotherapy 39:2583-2584.
153. Sabesan S, Duus JO, Domaille P, Kelm S & Paulson JC (1991) Synthesis of cluster sialoside inhibitors for influenza virus. Journal of the American Chemical Society 113:5865-5866.
154. Safrin S, McKinley G, McKeough M, Robinson D & Spruance SL (1994) Treatment of acyclovir-unresponsive cutaneous herpes simplex virus infection with topically applied SP-303. Antiviral Research 25:185-192.
155. Schilling M, Povinelli L, Krause P, Gravenstein M, Ambrozaitis A, Jones HH, Drinka P, Shult P, Powers D & Gravenstein S (1998) Efficacy of zanamivir for chemo prophylaxis of nursing home influenza outbreaks. Vaccine 16:1771-1774.
156. Scholtissek C, Quack G, Klenk HD & Webster RG (1998) How to overcome resistance of influenza A viruses against adamantane derivatives. Antiviral Research 37:83-95.
157. Schulman JL & Palese P (1975) Susceptibility of different strains of influenza A virus to the inhibitoiy effects of 2-deoxy-2,3-dehydro-n-trifluoracetylneuraminic acid (FANA). Virology 63:98-104.
158. Shi L, Summers DF, Peng Q & Galarza JM (1995) Influenza A virus RNA polymerase subunit PB2 is the endonuclease which cleaves host cell mRNA and functions only as the trimeric enzyme. Virology 208:38-47.
159. Shibata M, Aoki H, Tsurumi T, Sugiura Y, Nishiyama Y, Suzuki S & Maeno K (1983) Mechanism of uncoating of influenza B virus in MDCK cells: action of chloroquine. Journal of General Virology 64:1149-1156.
160. Shibata S, Yamamoto-Goshima F, Maeno K, Hanaichi T, Fujita Y, Nakajima K, Imai M, Komatsu T & Sugiura S (1993) Characterization of a temperature-sensitive influenza B virus mutant defective in NA. Journal of Virology 67:3264-3273.
161. Shigeta S, Mori S, Watanabe J, Baba M, Khenkin AM, Hill CL & Schinazi RF (1995) In vitro antimyxovirus and anti-human immunodeficiency virus activities of polyoxometalates. Antiviral Chemistry & Chemotherapy 6:114-122.
162. Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT & Robins RK
163. Sidwell RW, Huffman JH, Moscon BJ & Warren RP (1994) Influenza virus-inhibitory effects of intraperitoneally and aerosol-administered SP303, a plant flavonoid. Chemotherapy 40:42-50.
164. Sidwell RW, Huffman JH, Bailey KW, Wong MH, Nimrod A & Panet A (1996) Inhibitory effects of recombinant manganese superoxide dismutase on influenza virus infections in mice. Antimicrobial Agents and Chemotherapy 40:2626-2631.
165. Sidwell RW, Huffman JH, Barnard DL, Bailey KW, Wong MH, Morrison A, Syndergaard T & Kim CU (1998) Inhibition of influenza virus infections in mice by GS 4104, an orally effective influenza virus NA inhibitor. Antiviral Research 37:107-120.
166. Singh S, Jedrzejas MJ, Air GM, Luo M, Laver WG & Brouillette WJ (1995) Structure-based inhibitors of influenza virus sialidase. A benzoic acid lead with novel interaction. Journal of Medicinal Chemistry 38:3217-3225.
167. Sintchak MD, Fleming MA, Futer O, Raybuck SA, Chambers SP, Caron PR, Murcko MA & Wilson KP (1996) Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid. Cell 85:921-930.
168. Smith CB, Charette RP, Fox JP, Cooney MK & Hall CB (1980) Lack of effect of oral ribavirin in naturally occurring influenza A virus (H1N1) infection. Journal of Infectious Diseases 141:548-554.
169. Sollis SL, Smith PW, Howes PD, Cherry PC & Bethell RC (1996) Novel inhibitors of influenza sialidase related to GG167. Synthesis of 4-amino and guanidino-4H-2-carboxylic acid-6-propylamides; selective inhibitors of influenza A virus sialidase. Bioorganic and Medicinal Chemistry Letters 6:1805-1808.
170. Spaltenstein A & Whitesides GM (1991) Polyacrylamides bearing pendant a-sialoside groups strongly inhibit agglutination of erythrocytes by influenza virus. Journal of the American Chemical Society 113:686-687.
171. Staehli P (1990) Interferon-induced proteins and the antiviral state. Advances in Virus Research 33:147-200.
172. Staschke KA, Colacino JM, Baxter AJ, Air GM, Bansal A, Hornback WJ, Munroe JE & Laver WG (1995) Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en. Virology 214:642-646.
173. Staschke KA, Hatch SD, Tang JC, Hornback WJ, Munroe JE, Colacino JM & Muesing MA (1998) Inhibition of influenza virus HA-mediated membrane fusion by a compound related to podocarpic acid. Virology 248:264-274.
174. Stein DS, Creticos CM, Jackson GG, Bernstein JM, Hayden FG, Schiff GM & Bernstein DI (1987) Oral ribavirin treatment of influenza A and B. Antimicrobial Agents and Chemotherapy 31:1285-1287.
175. Streeter DG, Witkowski JT, Khare GP, Sidwell RW, Bauer RJ, Robins RK & Simon LN (1973) Mechanism of action of 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proceedings of the National Academy of Sciences, USA 70:1174-1178.
176. Streeter DG, Miller JP, Robins RK & Simon LN (1977) The enzymatic conversion of 1,2,4-triazole-3-carboxamide to ribavirin-5′-triphosphate and its relationship to the proposed mechanism of action. Annals of the New York Academy of Sciences 284:201-210.
177. Suarez DL, Perdue ML, Cox N, Rowe T, Bender C, Huang J & Swayne DE (1998) Comparisons of highly virulent H5N1 influenza A viruses isolated from humans and chickens from Hong Kong. Journal of Virology 72:6678-6688.
178. Subbarao K, Klimov A, Katz J, Regnery H, Lim W, Hall H, Perdue M, Swayne D, Bender C, Huang J, Hemphill M, Rowe T, Shaw M, Xu X, Fukuda K & Cox N (1998) Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 279:393-396.
179. Tai CY, Escarpe PA, Sidwell RW, Williams MA, Lew W, Wu H, Kim CU & Mendel DB (1998) Characterization of human influenza virus variants selected in vitro in the presence of the NA inhibitor GS 4071. Antimicrobial Agents and Chemotherapy 42:3234-3241.
180. Tan SL & Katze MG (1998) Biochemical and genetic evidence for complex formation between the influenza A virus NS1 protein and the interferon-induced PKR protein kinase. Journal of Interferon and Cytokine Research 18:757-766.
181. Tate RM & Repine JE (1983) Neutrophils and the adult respiratory distress syndrome. American Review of Respiratory Disease 128:552-559.
182. Taylor G (1993) A rational attack on influenza. Nature 363:401-402.
183. Thomas GP, Forsyth M, Penn CR & McCauley JW (1994) Inhibition of the growth of influenza viruses in vitro by 4-guanidino-2,4-dideoxy-N-acetylneuraminic acid. Antiviral Research 24:351-356.
184. Tisdale M, Appleyard G, Tuttle JV, Nelson DJ, Nusinoff-Lehrman S, Al Nakib W, Stables JN, Purifoy DJM, Powell KL & Darby G (1993) Inhibition of influenza A and B viruses by 2′-deoxy-2′-fluororibosides. Antiviral Chemistry & Chemotherapy 4:281-287.
185. Tisdale M, Ellis M, Klumpp K, Court S & Ford M (1995) Inhibition of influenza virus transcription by 2′-deoxy-2′-fluoroguanosine. Antimicrobial Agents and Chemotherapy 39:2454-2458.
186. Togo Y & McCracken EA (1976) Double-blind clinical assessment of ribavirin (Virazole) in the prevention of induced infection with type B influenza virus. Journal of Infectious Diseases 133:Suppl. A109-113.
187. Tomassini J, Selnick H, Davies ME, Armstrong ME, Baldwin J, Bourgeois M, Hastings J, Hazuda D, Lewis J, McClements W, Ponticello G, Radzilowksi E, Smith G, Tebben A & Wolfe A (1994) Inhibition of cap (m7GpppXm)-dependent endonuclease of influenza virus by 4-substituted 2,4-dioxobutanoic acid compounds. Antimicrobial Agents and Chemotherapy 38:2827-2837.
188. Tomassini J, Davies ME, Hastings JC, Lingham R, Mojena M, Raghoobar SL, Singh SB, Tkacz JS & Goetz MA (1996) A novel antiviral agent which inhibits the endonuclease of influenza viruses. Antimicrobial Agents and Chemotherapy 40:1189-1193.
189. Tu Q, Pinto LH, Luo G, Shaughnessy MA, Mullaney D, Kurtz S, Krystal M & Lamb RA (1996) Characterization of inhibition of M2 ion channel activity by BL-1743, an inhibitor of influenza A virus. Journal of Virology 70:4246-4252.
190. Tuttle JV, Tisdale M & Krenitsky TA (1993) Purine 2′-deoxy-2′-fluororibosides as antiinfluenza virus agents. Journal of Medicinal Chemistry 36:119-125.
191. Ulmanen I, Broni BA & Krug RM (1981) Role of two of the influenza virus core P proteins in recognizing cap 1 structures (m7GpppNm) on RNAs and in initiating viral RNA transcription. Proceedings of the National Academy of Sciences, USA 78:7355-7359.
192. Van Daal GJ, Bos JA, Eijking EP, Gommers D, Hannappel E & Lachmann B (1992) Surfactant replacement therapy improves pulmonary mechanics in end-stage influenza A pneumonia in mice. American Review of Respiratory Diseases 145:859-863.
193. Varghese JN & Colman PM (1991) Three-dimensional structure of the NA of influenza virus A/Tokyo/3/67 at 2.2 Å resolution. Journal of Molecular Biology 221:473-486.
194. Varghese JN, Laver WG &, Colman PM (1983) Structure of the influenza glycoprotein antigen NA at 2.9 Å resolution. Nature 303:35-40.
195. Varghese JN, McKimm-Breschkin JL, Caldwell JB, Kort AA & Colman PM (1992) The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins 14:327-332.
196. Varghese JN, Epa VC & Colman PM (1995) Three dimensional structure of the complex of 4-guanidino-Neu5Ac2en and influenza virus NA. Protein Science 4:1081-1087.
197. Varghese JN, Smith PW, Sollis SL, Blick TJ, Sahasrabudhe A, McKimm-Breschkin JL & Colman PM (1998) Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus NA. Structure 6:735-746.
198. von Itzstein M, Barry JG & Chong AKJ (1993a) The development of potential anti-influenza drugs. Current Opinions in Therapeutic Patents 3:1755-1762.
199. von Itzstein M, Wu WY, Kok GK, Pegg MS, Dyason JC, Jin B, Phan TV, Smythe ML, White HF, Oliver SW, Colman PM, Varghese JN, Ryan JM, Woods JM, Bethell RC, Hotham VJ, Cameron JM & Penn CR (1993b) Rational design of potent sialidase based inhibitors of influenza virus replication. Nature 363:418-423.
200. Wade RC (1997) 'Flu' and structure-based drug design. Structure 5:1139-1145.
201. Walker JA, Sakaguchi T, Matsuda Y, Yoshida T & Kawaoka Y (1992) Location and character of the cellular enzyme that cleaves the HA of a virulent avian influenza virus. Virology 190:278-287.
202. Walker JA, Molloy SS, Thomas G, Sakaguchi T, Yoshida T, Chambers TM & Kawaoka Y (1994) Sequence specificity of furin, a proprotein-processing endoprotease, for the HA of a virulent avian influenza virus. Journal of Virology 68:1213-1218.
203. Walker JB, Hussey EK, Treanor JJ, Montalvo A Jr & Hayden FG (1997) Effects of the NA inhibitor zanamivir on otologic manifestations of experimental human influenza. Journal of Infectious Diseases 176:1417-1422.
204. Webster RG & Kawaoka Y (1994) Influenza: an emerging and reemerging disease. Seminars in Virology 5:103-111.
205. Webster RG, Bean WJ, Gorman OT, Chambers TM & Kawaoka Y (1992) Evolution and ecology of influenza A viruses. Microbiological Reviews 56:152-179.
206. White CL, Janakiraman MN, Laver WG, Philippon C, Vasella A, Air GM & Luo M (1995) A sialic acid-derived phosphonate analog inhibits different strains of influenza virus NA with different efficiencies. Journal of Molecular Biology 245:623-634.
207. White JM (1990) Viral and cellular membrane fusion proteins. Annual Review of Physiology 52:675-697.
208. White J, Matlin K & Helenius A (1981) Cell fusion by Semliki forest, influenza, and vesicular stomatitis virus. Journal of Cell Biology 89:674-679.
209. Wiley DC & Skehel JJ (1987) The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annual Review of Biochemistry 56:365-394.
210. Wiley DC, Wilson IA & Skehel JJ (1981) Structural identification of the antibody-binding sites of Hong Kong influenza virus haemagglutinin and their involvement in antigenic variation. Nature 289:373-378.
211. Williams M, Bischofberger N, Swaminathan S & Kim CU (1995) Synthesis and influenza NA inhibitory activity of aromatic analogues of sialic acid. Bioorganic and Medicinal Chemistry Letters 5:2251-2254.
212. Wilson IA, Skehel JJ & Wiley DC (1981) Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 Å resolution. Nature 289:366-373.
213. Witkowski JT, Robins RK, Sidwell RW & Simon LN (1972) The design, synthesis, and broad spectrum antiviral activity of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosides. Journal of Medicinal Chemistry 15:1150-1154.
214. Woods JM, Bethell RC, Coates JAV, Healy N, Hiscox SA, Pearson BA, Ryan DM, Ticehurst J, Tilling J, Walcott SM & Penn CR (1993) 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (NA) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrobial Agents and Chemotherapy 37:1473-1479.
215. Wray SK, Gilbert BE, Noall MW & Knight V (1985) Mode of action of ribavirin: effect of nucleotide pool alterations on influenza virus ribonucleoprotein synthesis. Antiviral Research 5:29-37.
216. Wyde PR, Ambrose MW, Meyer HL & Gilbert BE (1990) Toxicity and antiviral activity of LY253963 against respiratory syncytial virus and parainfluenza type 3 viruses in tissue culture and in cotton rats. Antiviral Research 14:237-248.
217. Yamamoto N, Schols D, De Clercq E, Debyser Z, Pauwels R, Balzarini J, Nakashima H, Baba M, Hosoya M, Snoeck R, Neyts J, Andrei G, Murrer RA, Theobald B, Bossard G, Henson G, Abrams M & Picker D (1992) Mechanism of anti-human immunodeficiency virus action of polyoxometalates, a class of broad spectrum antiviral agents. Molecular Pharmacology 42:1109-1117.
218. Ye Z, Baylor NW & Wagner RR (1988) Transcription-inhibition and RNA-binding domains of influenza A virus matrix protein mapped with anti-idiotypic antibodies and synthetic peptides. Journal of Virology 63:3586-3594.
219. Ye Z & Wagner RR (1992) Down regulation of vesicular stomatitis virus transcription by the matrix protein of influenza virus. Journal of General Virology 73:743-748.
220. Ye Z, Pal R, Fox JW, Wagner RR (1987) Functional and antigenic domains of the matrix (M) protein of influenza A virus. Journal of Virology 61:3239-3246.
221. Zerial A, Thuong NT & Helene C (1987) Selective inhibition of the cytopathic effect of type A influenza viruses by oligodeoxynucleotides covalently linked to an intercalating agent. Nucleic Acids Research 15:9909-9919.
222. Zhirnov OP, Ovcharenko AV & Bukrinskaya AG (1984) Suppression of influenza virus replication in infected mice by protease inhibitors. Journal of General Virology 65:191-196.